Abstract
We classified drug-induced uveitis related to Immune Checkpoint inhibitors (ICIs) and MAP-kinase pathway inhibitors (MAPKi), including BRAF-inhibitors (BRAFi) and MEK-inhibitors (MEKi), according ophthalmological examination. Cases were retrieved from the French pharmacovigilance database (FPVD) which included all adverse drug reactions (ADR) registred by the French Regional Pharmacovigilance Network. We collected 113 cases of drug-induced uveitis (46 ICI-related and 67 MAPKi-related). The classification analysis identified four clusters. ICI were associated with anterior, posterior and panuveitis with severe manifestations such as retinal vasculitis and optic neuropathy. BRAFi were associated with anterior and panuveitis. MEKi inhibitors were associated with early serous-retinal detachment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
